Sage Therapeutics Inc (NASDAQ: SAGE) stock suffered a major decline of -10.9% on 8/1/24. The shares closed at $9.76. Trading volume in this decline was normal. The stock has declined -6.0% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
SAGE is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Sage Therapeutics has a slightly negative Appreciation Score of 34 and a poor Power Rating of 15, leading to the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment